Reported 1 day ago
Protagonist Therapeutics, Inc. (PTGX) is seen as a promising investment opportunity, bolstered by robust clinical advancements and overlooked financial fundamentals. With a market cap of $3.6 billion and notable pipelines like Icotrokinra and Rusfertide, PTGX is positioned to capture significant market share in the IL-23 class and generate substantial royalties. The company's strong balance sheet and multiple near-term catalysts further enhance its risk-reward profile. While PTGX's potential is acknowledged, some analysts suggest that AI-focused stocks may present greater upside potential.
Source: YAHOO